INTEGRIS-IPF

Clinical Trial

What to expect in the INTEGRIS-IPF clinical trial

The INTEGRIS-IPF clinical trial is studying PLN-74809, an oral investigational medicine designed to treat the underlying cause of lung fibrosis (when tissue becomes damaged and scarred, affecting normal function of the organ). The medicine has been tested in over 180 individuals already and was generally well tolerated and safe. It is taken once per day for 12 weeks.

By stopping the cellular process that causes fibrosis, PLN-74809 may have the potential to slow or stop the progressive decline in lung function that happens with IPF. This study will help determine if PLN-74809 affects worsening of the disease and improves quality of life.

Can I participate?

Talk to your doctor about participating in this clinical trial if:

  • You are a patient with a confirmed diagnosis of large duct primary sclerosing cholangitis, or PSC
  • You are over between the ages of 18 and 75
  • Your serum ALT concentration is between 1.5 and 5 times the upper limit of normal

COVID-19 Impact

We are committed to protecting patients and clinicians from the spread of COVID-19. Our clinical trial sites are following all government and institutional safety guidelines. Additionally, we are minimizing participants’ visits to trial sites by offering home-health solutions – with some tests and measures conducted through telehealth appointments in participant homes. Pliant Therapeutics will continue to work closely with site investigators and update our practices accordingly to ensure the safe continuation of the trial.

For more information

For more information visit clinicaltrials.gov or contact us to learn more about this trial clinicaltrials@pliantrx.com